Mayo Clinic

Early is Good Announces Collaboration with Mayo Clinic to Develop a Comprehensive Liquid Biopsy Test for Men with Advanced Prostate Cancer

Retrieved on: 
Tuesday, April 9, 2024
Oncology, Medical Devices, Health, Consumer, Men, Biotechnology, EIG, Prostate cancer, Disease, Education, Patient, Mayo Clinic, Research, Death, Cancer, Liquid biopsy, Integration platform, Pharmaceutical industry

Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.

Key Points: 
  • Early is Good (EIG), a diagnostic company pioneering multi-omic technology, is pleased to announce a collaboration with Mayo Clinic to develop a comprehensive liquid biopsy for men with advanced prostate cancer.
  • This collaboration to develop a comprehensive multi-omic test aims to significantly improve patient outcomes for men with advanced prostate cancer," says Thakshila Liyanage, Ph.D., Founder & CEO of Early is Good.
  • This novel liquid biopsy test seeks to enable comprehensive care plans for men with mCRPC.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Friday, April 5, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Clinical Trials, Biotechnology, CGM, MARD, Venous blood, Know Labs, Machine, APS, Mayo Clinic, Blood, American Physiological Society, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

Retrieved on: 
Thursday, April 4, 2024
Research, Professional Services, Data Management, Oncology, Technology, Medical Devices, Genetics, Artificial Intelligence, Health Technology, Data Analytics, Science, Biotechnology, Health, Cloud, Algorithm, Individualized medicine, Exact sciences, Disease, Physician, Risk, Patient, Mayo Clinic, DNA, Cancer, Multimedia, Collection, Medical imaging

Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.

Key Points: 
  • Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients.
  • View the full release here: https://www.businesswire.com/news/home/20240404198461/en/
    Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center (Graphic: Business Wire)
    “This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy , chairman and chief executive officer, Exact Sciences.
  • The Riskguard hereditary cancer test helps patients and their physicians understand the patients' hereditary risk of cancer.
  • “It will also lead to new scientific and clinical discoveries by Mayo Clinic Comprehensive Cancer Center and Mayo Clinic's Center for Individualized Medicine .”
    Patients will consent to have the tests performed and to have the data shared with Mayo Clinic.

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
Tuesday, April 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer

Retrieved on: 
Thursday, March 28, 2024
Other Health, Health, Science, Research, Oncology, Cancer, Incidence, Risk, Esophageal cancer, Patient, Education, Mayo Clinic, Hepatology, EAC, Exact sciences, DNA, MD, Division, HGD, FDA, Food, Medical device

“In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.

Key Points: 
  • “In collaborating with Exact Sciences, we are able to study the potential of a minimally invasive, non-endoscopic screening tool currently in development in patients at higher risk for EAC.
  • “In esophageal cancer, earlier screening and detection will provide an important advance, as we have seen in other cancers.
  • We are collaborating with Mayo Clinic to continue the development of the Oncoguard Esophagus test as a minimally invasive solution for earlier detection of EAC and its precursors.”
    The Oncoguard Esophagus test is currently under development and features of the test described above are outlining current development goals.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

SHL Telemedicine Receives Buy Rating with $11.00 Price Target

Retrieved on: 
Thursday, March 14, 2024
Software, Telemedicine, Virtual Medicine, Finance, Health, Health Technology, Professional Services, Technology, Apps, Applications, Research, The Wall Street Journal, Growth, Clinical professor, Mayo Clinic, Telehealth, SHL, Imperial College London, Clinical trial, Wells Fargo, FINRA, Pharmaceutical industry

SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target.

Key Points: 
  • SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is pleased to announce that Litchfield Hills Research, a leading equity research firm has initiated coverage of with a 'Buy' rating and an $11.00 price target.
  • This price target represents a significant premium over the company's current share price, highlighting the firm's confidence in SHL's growth trajectory and market position.
  • The equity research report emphasizes SHL Telemedicine's innovative approach and expanding market opportunities, noting that "SHLT is a pure-play in the rapidly expanding $115B telemedicine market.
  • The $11.00 price target is based on a comprehensive analysis of the company's financial health, growth prospects, and the expanding market for telemedicine services.

The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study

Retrieved on: 
Wednesday, March 13, 2024
Oncology, Medical Supplies, Health, Medical Devices, Other Health, General Health, Clinical Trials, Colonoscopy, Conditional sentence, Colorectal cancer, Alaska Natives, Webcast, Patient, Mayo Clinic, FIT, Exact sciences, Research, History, Cancer, CRC, Carcinoma, Pharmaceutical industry

“Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.

Key Points: 
  • “Cologuard Plus is highly sensitive for detecting colorectal cancer,” said Thomas F. Imperiale, MD, professor of medicine at the Indiana University School of Medicine, research scientist at the Regenstrief Institute, and principal investigator for the BLUE-C study.
  • BLUE-C investigators also collected blood samples for evaluation of a blood-based CRC screening test developed by Exact Sciences.
  • This enrollment diversity helps ensure that the BLUE-C findings and Cologuard Plus are relevant for all screen-eligible individuals, regardless of race or ethnicity.
  • ET to discuss results of the pivotal BLUE-C study.

Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Pharmaceutical, Health, GC, Obesity, Endocrinology, Clinical professor, Associate, Risk, Patient, GCS, Mayo Clinic, Androgen, Șaeș, CAH, Endocrine system, Safety, Workforce, Medical director, ACTH, Pharmaceutical industry

Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.

Key Points: 
  • Preliminary pharmacokinetic analysis suggests that tildacerfont is cleared more rapidly in children than in adult CAH patients.
  • 70% of patients with elevated baseline A4 values (16 of 23 patients) demonstrated an A4 reduction at week 4.
  • “The CAHptain-205 study results demonstrate safety and tolerability in pediatric CAH patients with weight-adjusted tildacerfont doses up to 200mg daily.
  • An archived copy of the call will be available on the events section of the company’s investor relations website for approximately 90 days.

Fifty-Five Percent of Hypertension Patients Said They Have Issues Sending Results from Bluetooth®-Connected Blood Pressure Monitors

Retrieved on: 
Monday, March 11, 2024
Health, Medical Devices, Technology, Practice Management, Health Technology, Mobile, Wireless, Cardiology, Blood pressure, Disease, Vital signs, Diabetes, Patient, Mayo Clinic, Switch, Smart meter, AT&T, Hypertension, RPM, Mobile phone

A majority of patients, however, have issues sending their readings to a healthcare professional when using remote monitoring systems that require Bluetooth®-connected devices, apps, and hubs.

Key Points: 
  • A majority of patients, however, have issues sending their readings to a healthcare professional when using remote monitoring systems that require Bluetooth®-connected devices, apps, and hubs.
  • Only about 25% of people with hypertension have their condition under control, according to the Centers for Disease Control and Prevention1 and the Mayo Clinic lists home monitoring as a key factor in helping patients control their blood pressure.
  • In the 2024 National Hypertension Survey, 55% of respondents said they have some type of issue sending their reading when using a Bluetooth-enabled blood pressure monitor.
  • And 30% said they always have an issue, which is a significant increase from the 8% in the 2023 National Hypertension Survey.